SEC Form 4 · accession 0001543077-16-000008
ARGOS THERAPEUTICS INC · ARGS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey D Abbey
Officer — Chief Executive Officer · Director
Period of report
Jun 13, 2016
Accepted (ET)
Jun 15, 2016 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001105533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 13, 2016 | A | 10,924 | $0.00 | A | 109,620 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $7.41 | Jun 13, 2016 | A | 250,000 | A | — | Jun 12, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. The restricted stock units vest in twelve equal monthly installments beginning June 30, 2016. Vested shares will be delivered to the reporting person on each vesting date.
- F2Includes 2,002 shares of common stock acquired pursuant to the 2014 Employee Stock Purchase Plan on March 10, 2016.
- F3This option was granted on June 13, 2016 and vests as to 25% of the shares underlying this option on June 13, 2017, with the remaining 75% of the shares underlying this option vesting in equal amounts monthly over the next three years beginning June 13, 2017.